| 微粒化非诺贝特治疗高脂血症的临床观察 |
| |
| 引用本文： | 吴贤仁,黄林喜.微粒化非诺贝特治疗高脂血症的临床观察[J].岭南急诊医学杂志,2001,6(1):10-12. |
| |
| 作者姓名： | 吴贤仁 黄林喜 |
| |
| 作者单位： | 广东省汕头大学医学院附一院内科,515041 |
| |
| 摘 要： | 目的:观察微粒化非诺贝特对高脂血症的疗效与安全性。方法:用开放、随机对照方式,应用非诺贝特和多烯康治疗高脂血症12周,记录病人一般资料和治疗前后有关检查结果及副作用。结果:非诺贝特组服药12周后血清胆固醇(TC)、甘油三酯(TG)、低胆固醇脂蛋白(LDL-C)水平与O周比较分别降低18.9％(P
|
| 关 键 词： | 非诺贝特 多烯康 高脂血症 |
Assessment of Fenofibrate Micronised Lipanthl 200m Therapy in Hyperlipidemia |
| |
| Wu Xianren,Huang Linxi.Assessment of Fenofibrate Micronised Lipanthl 200m Therapy in Hyperlipidemia[J].Lingnan Journal of Emergency Medicine,2001,6(1):10-12. |
| |
| Authors: | Wu Xianren Huang Linxi |
| |
| Institution: | Wu Xianren,Huang Linxi First affiliated hospital,Shantou University Medical College,515041 |
| |
| Abstract: | Objective: To assess the effective and safety of Fenofibrate Micronised Lipanthyl 200m in hyperlipidemia. Mehtbod: In an open and randomized prospective study, 98 patients with hyperlipidemia were divided into two groups, which one was treated with Fenofibrate, the other with Duoxikang for 12 weeks. Clinical data, laboratory results and side effects of both therapies were employeed. Results: At the end of the study, the rate of reduce of serum cholesterol, triglyceride, low density lipoprotein were 18.9% (P<0.01), 44% (P<0.001), 13% (P<0.05) in order in Fenofibrate group, meanwhile, in Duoxikang group, were 11%, 19%, 13.7% (P<0.05). The effective rate of 79.1% in Fenofibrate group and 48.8% in Duoxikang group were seen, therefore Fenofibrate therapy was more effective than Duoxikang therapy in hyperlipidemia( P
|
| |
| Keywords: | Fenofibrate Duoxikang hyperlipidemia |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
